Although recent reports have also shown that Oct-4 is re-expressed in different human carcinomas, implicating Oct-4 as a potential diagnostic marker in malignancy [25,26], whether Oct-4 expression can be used as a diagnostic tool to monitor the clinical prognosis of NSCLC patients has not been previously substantiated. The gene discussed is POU5F1; the disease is carcinoma.